This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Genzyme To Present New Data From AUBAGIO® And LEMTRADATM Clinical Development Programs At ECTRIMS

Stocks in this article: SAN SNY

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today new data from Genzyme’s clinical development programs for AUBAGIO ® (teriflunomide) and LEMTRADA TM (alemtuzumab) will be presented at the 28 th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

“The data to be presented at ECTRIMS are a reflection not only of the comprehensive clinical development programs supporting AUBAGIO and LEMTRADA, but of the unique commitment and substantial progress Genzyme has made to date in bringing forward differentiated therapies in multiple sclerosis,” said Genzyme CEO and President, David Meeker.

Once-daily, oral AUBAGIO is now commercially available in the U.S. following FDA approval in patients with relapsing forms of MS. Marketing applications for AUBAGIO and LEMTRADA are currently under review by the EMA and other regulatory authorities.

Key data from across the company’s clinical development programs to be presented are as follows. Abstracts are available on the ECTRIMS website.

TOWER ( Teriflunomide Oral in people With relapsing multipl E scle Rosis)

TOWER is a randomized Phase III trial assessing once-daily oral AUBAGIO (teriflunomide) in patients with relapsing multiple sclerosis. It is the second Phase III study for AUBAGIO.

  • The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study (Parallel Session 12 – 153; October 12; 3:10 p.m. CEST, 9:10 a.m. EDT).

CARE-MS II ( Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis II)

CARE-MS II was a randomized Phase III clinical trial designed to evaluate whether the investigational MS therapy LEMTRADA (alemtuzumab) could achieve meaningful efficacy and safety improvements over the approved, active comparator Rebif (subcutaneous interferon beta-1a 44 mcg).

  • Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: subgroup analyses by previous DMT use (Poster Session 1 – P483; October 11; 3:30 p.m. CEST, 9:30 a.m. EDT).
  • Disability improvement with alemtuzumab vs. interferon beta-1a in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (Poster Session 2 – P922; October 12; 3:30 p.m. CEST, 9:30 a.m. EDT).
  • Effect of alemtuzumab vs. Rebif® on brain MRI measurements: Results of CARE-MS II (Poster Session 2 – P877; October 12; 3:30 p.m. CEST, 9:30 a.m. EDT).
  • Safety of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (Poster Session 1 – P545; October 11; 3:30 p.m. CEST, 9:30 a.m. EDT).

Additional Genzyme MS portfolio data, in addition to the Genzyme satellite symposia to be featured at ECTRIMS include:

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs